Bladder Adjuvant Radiotherapy: Phase III Multicenter Randomized Controlled Trial of Adjuvant Radiotherapy or Observation for Postcystectomy Muscle-Invasive Bladder Cancer

Gastrointestinal Cancer

Simultaneous integrated boost intensity-modulated radiotherapy with or without concurrent chemotherapy in patients with esophageal squamous cell carcinoma: A multicenter, open-label, randomized, phase III clinical trial

Int J Cancer

Han W, Gao L, Wang X, Li C, Zhou Z, Deng L, Wang W, Liu W, Wang X, Chen D, Feng Q, Bi N, Zhang T, Wang J, Zhai Y, Zhao Y, Xiao Z, Jing‐Jin‐Ji Esophageal and Esophagogastric Cancer Radiotherapy Oncology Group (3JECROG)

doi: 10.1002/ijc.70176

Genitourinary Cancer

Indirect Comparison of Neoadjuvant Treatment Strategies for Muscle-Invasive Bladder Cancer: ddMVAC and Perioperative Durvalumab-Gemcitabine-Cisplatin Versus Gemcitabine-Cisplatin: A Systematic Review and Network Meta-Analysis of Randomised Controlled Trials

Int J Cancer

Mangold MH, Baumann G, Wieland VLS, Carl N, Renner LV, Studier-Fischer A, Menold H, Zschäbitz S, Wessels F, Westhoff N, Michel MS, Kowalewski KF, Haney-Aubert CM

doi: 10.1002/ijc.70525

RECOMMENDED

Breast Cancer

Adjuvant Epirubicin Plus Cyclophosphamide Followed by Taxanes With or Without Carboplatin in Early-Stage Triple-Negative Breast Cancer (RJBC 1501): A Randomized Phase III Trial

★ 3 Recommended by Prof. Dr Beat Thürlimann, Faculty Member

J Clin Oncol

Chen X, Huang J, Shi H, Zhu J, Wu W, Ye G, He Q, Shi Y, Zhang A, Xie X, Wang X, Chen X, Wu W, Wu J, Li Z, Li Z, Dai Y, Ren W, Shao Q, Chen Y, Zeng Y, Zhang F, Dong S, Pegram MD, Shen K

doi: 10.1200/JCO-25-02412

Breast Cancer

Addition of Carboplatin to Sequential Taxane-Anthracycline Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer: A Phase III Randomized Controlled Trial

J Clin Oncol

Gupta S, Nair N, Hawaldar RW, Joshi S, Gulia S, Shet T, Sarin R, Parmar V, Desai S, Ghosh J, Wadasadawala T, Vanmali V, Panhale T, Parab P, Patil A, Chitkara G, Rath S, Bajpai J, Pathak R, Popat P, Thakur M, Badwe RA

doi: 10.1200/JCO-25-01023

Gynecologic Cancer

Fuzuloparib with or without apatinib as maintenance therapy in newly diagnosed, advanced ovarian cancer (FZOCUS-1): A multicenter, randomized, double-blind, placebo-controlled phase 3 trial

CA Cancer J Clin

Wu L, Wang J, Li Q, Wang D, Zhang C, Tang J, Zhang G, Hao M, Yao D, Gao Q, Zhang Y, An R, Yin R, Wang L, Xia B, Zhou Q, Yang H, Zhu J, Jiang K, Chen Z, Wu Q, Duan W, Huang Y, Zhang H, Wei S, Li G, Meng Y, Wang K, Yang X, Huang X, Pan L, Yu J, Lou G, Zhang Y, Zhou H, Guo X, Yang H, Cheng X, Li X, Wang W, Zhao H, Li Y, Yang Y, Lin A, Cheng W, Chen L, Xie X, Di W, Hu Y, Chen M, Wen H, Cai L, Wu X, Lin Z, Wang Q, Yang X, Li N

doi: 10.3322/caac.70042

Genitourinary Cancer

UGN-102 for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer: 24-Month Duration of Response Results From the Phase 3 ENVISION Trial

J Urol

Prasad SM, Shishkov D, Mihaylov NV, Genov P, Terzi V, Kates M, Huang WC, Louie MJ, Burger B, Meads A, Schoenberg M

doi: 10.1097/JU.0000000000005041

Head and Neck Cancer

De-escalated adjuvant radiotherapy versus standard adjuvant treatment for human papillomavirus-associated oropharyngeal squamous cell carcinoma (MC1675): a phase 3, open-label, randomised controlled trial

Lancet Oncol

Ma D, Price K, Moore E, Patel S, Hinni M, Routman D, Fruth B, Foster N, Van Abel K, Yin L, Neben-Wittich M, Garces Y, McGee L, Lester S, Rwigema JC, Holtzman A, Price D, Janus J, Kasperbauer J, Chintakuntlawar A, Garcia J, Foote R

doi: 10.1016/S1470-2045(25)00324-9

Genitourinary Cancer

ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer

N Engl J Med

Powles T, Kann AG, Castellano D, Gross-Goupil M, Nishiyama H, Bracarda S, Bjerggaard Jensen J, Makaroff L, Jiang S, Ku JH, Park SH, Reig Torras O, Ye D, Maruzzo M, Necchi A, Morales-Barrera R, Giunta EF, Lee JL, Tortora G, Ürün Y, Dolowy L, Erdem D, Pinto A, Grando F, Zou W, Assaf ZJ, Vuky J, Degaonkar V, Steinberg EE, Bellmunt J, Gschwend JE, IMvigor011 Investigators

doi: 10.1056/NEJMoa2511885

Genitourinary Cancer

Bacillus Calmette-Guérin Plus Mitomycin Versus Bacillus Calmette-Guérin Alone for Bacillus Calmette-Guérin-naïve Non-muscle-invasive Bladder Cancer: A Randomised Phase 3 Trial (ANZUP 1301)

Eur Urol

Hayne D, Zhang AY, Thomas H, Krieger L, Ischia J, Anderson P, Srivastav RK, Green W, Grummet J, Bastick PA, Beardsley EK, Blatt A, Patel M, Chan L, Mitterdorfer A, Roberts M, Sengupta S, Winter M, Marx G, Bishop C, Cheung L, Hawks C, Martin A, McCombie SP, Redfern AD, Davis ID, Stockler MR

doi: 10.1016/j.eururo.2026.01.009

Related content

Simultaneous integrated boost intensity-modulated radiotherapy with or without concurrent chemotherapy in patients with esophageal squamous cell carcinoma: A multicenter, open-label, randomized, phase III clinical trial

Indirect Comparison of Neoadjuvant Treatment Strategies for Muscle-Invasive Bladder Cancer: ddMVAC and Perioperative Durvalumab-Gemcitabine-Cisplatin Versus Gemcitabine-Cisplatin: A Systematic Review and Network Meta-Analysis of Randomised Controlled Trials

Adjuvant Epirubicin Plus Cyclophosphamide Followed by Taxanes With or Without Carboplatin in Early-Stage Triple-Negative Breast Cancer (RJBC 1501): A Randomized Phase III Trial

Addition of Carboplatin to Sequential Taxane-Anthracycline Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer: A Phase III Randomized Controlled Trial

Fuzuloparib with or without apatinib as maintenance therapy in newly diagnosed, advanced ovarian cancer (FZOCUS-1): A multicenter, randomized, double-blind, placebo-controlled phase 3 trial

UGN-102 for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer: 24-Month Duration of Response Results From the Phase 3 ENVISION Trial

De-escalated adjuvant radiotherapy versus standard adjuvant treatment for human papillomavirus-associated oropharyngeal squamous cell carcinoma (MC1675): a phase 3, open-label, randomised controlled trial

ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer

Bacillus Calmette-Guérin Plus Mitomycin Versus Bacillus Calmette-Guérin Alone for Bacillus Calmette-Guérin-naïve Non-muscle-invasive Bladder Cancer: A Randomised Phase 3 Trial (ANZUP 1301)